Oruka Therapeutics (NASDAQ:ORKA) Insider Joana Goncalves Sells 7,000 Shares

April 16, 2026 by InsiderTrades.com

Key Points

Insider sale: Joana Goncalves sold 7,000 shares on April 15 at an average price of $66.12 (≈$462,840), cutting her stake by ~17.3% to 33,377 shares; the trade was executed under a pre‑arranged Rule 10b5‑1 plan after multiple sales earlier this year.
Market and analyst backdrop: ORKA is trading near its 1‑year high with 50‑day/200‑day moving averages of $41.37/$33.23 and a $3.25B market cap, while analysts remain bullish (10 Buys, average price target $78.90) despite continued multi‑year loss forecasts.
Company focus: Oruka is a clinical‑stage biopharma developing stapled peptide therapies, with lead candidate ONCT‑01 in Phase 1 for advanced solid tumors, so valuation hinges on future clinical progress.

Oruka Therapeutics, Inc. (NASDAQ:ORKA - Get Free Report) insider Joana Goncalves sold 7,000 shares of the stock in a transaction that occurred on Wednesday, April 15th. The shares were sold at an average price of $66.12, for a total value of $462,840.00. Following the completion of the sale, the insider directly owned 33,377 shares of the company's stock, valued at $2,206,887.24. The trade was a 17.34% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Joana Goncalves also recently made the following trade(s):

On Monday, March 16th, Joana Goncalves sold 7,641 shares of Oruka Therapeutics stock. The stock was sold at an average price of $40.91, for a total value of $312,593.31.
On Tuesday, February 17th, Joana Goncalves sold 7,000 shares of Oruka Therapeutics stock. The stock was sold at an average price of $32.37, for a total value of $226,590.00.
On Thursday, January 15th, Joana Goncalves sold 7,000 shares of Oruka Therapeutics stock. The stock was sold at an average price of $31.81, for a total value of $222,670.00.

Oruka Therapeutics Price Performance

Shares of NASDAQ ORKA opened at $65.55 on Thursday. The stock has a fifty day moving average price of $41.37 and a 200 day moving average price of $33.23. Oruka Therapeutics, Inc. has a 1-year low of $8.31 and a 1-year high of $67.94. The company has a market cap of $3.25 billion, a PE ratio of -35.24 and a beta of -0.54.

Oruka Therapeutics (NASDAQ:ORKA - Get Free Report) last issued its quarterly earnings results on Thursday, March 12th. The company reported ($0.45) earnings per share for the quarter, topping the consensus estimate of ($0.61) by $0.16. Analysts anticipate that Oruka Therapeutics, Inc. will post -3.41 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

ORKA has been the subject of several recent research reports. Guggenheim reaffirmed a "buy" rating and set a $125.00 price target on shares of Oruka Therapeutics in a report on Monday. UBS Group increased their price target on Oruka Therapeutics from $50.00 to $75.00 and gave the stock a "buy" rating in a report on Monday, April 6th. Stifel Nicolaus increased their price objective on Oruka Therapeutics from $47.00 to $72.00 and gave the stock a "buy" rating in a research report on Friday, March 13th. Wall Street Zen upgraded Oruka Therapeutics from a "sell" rating to a "hold" rating in a research report on Monday, March 16th. Finally, HC Wainwright increased their price objective on Oruka Therapeutics from $40.00 to $70.00 and gave the stock a "buy" rating in a research report on Monday. Ten research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Oruka Therapeutics currently has an average rating of "Moderate Buy" and an average price target of $78.90.

Get Our Latest Analysis on Oruka Therapeutics

Key Stories Impacting Oruka Therapeutics

Here are the key news stories impacting Oruka Therapeutics this week:

Positive Sentiment: Wedbush raised its price target to $85 and assigned an "outperform" rating, a notable bullish signal that increases upside expectations for ORKA. Wedbush raises ORKA target
Positive Sentiment: BTIG boosted its price target to $78, adding further analyst-driven momentum that may support buying interest. BTIG raises ORKA target to $78
Positive Sentiment: HC Wainwright reiterated a "Buy" rating and a $70 target while publishing multi‑quarter and FY2026–FY2027 EPS forecasts (FY2027: -$3.55), signaling continued analyst conviction despite losses; this sustained buy-side research supports the stock’s rally. HC Wainwright coverage
Neutral Sentiment: An insider (Joana Goncalves) sold 7,000 shares under a pre‑arranged Rule 10b5‑1 plan, reducing her stake ~17.3%; because the sale was pre‑planned and disclosed via SEC Form 4, it’s less likely to signal new negative information, but it can still be perceived as supply pressure. SEC Form 4
Negative Sentiment: Consensus and firm forecasts confirm continued multi‑year losses (consensus FY current year ~ -$3.41 EPS; HC Wainwright FY2027 -$3.55), which keeps valuation reliant on future clinical/ commercial successes and may cap multiple expansion despite high price‑target activity.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of ORKA. Goldman Sachs Group Inc. purchased a new position in Oruka Therapeutics in the first quarter worth $2,505,000. JPMorgan Chase & Co. raised its position in Oruka Therapeutics by 567.7% in the second quarter. JPMorgan Chase & Co. now owns 15,425 shares of the company's stock worth $173,000 after acquiring an additional 13,115 shares in the last quarter. Legal & General Group Plc purchased a new position in Oruka Therapeutics in the second quarter worth $28,000. Rhumbline Advisers purchased a new position in Oruka Therapeutics in the second quarter worth $320,000. Finally, New York State Common Retirement Fund purchased a new position in Oruka Therapeutics in the second quarter worth $96,000. Hedge funds and other institutional investors own 56.44% of the company's stock.

Oruka Therapeutics Company Profile

(Get Free Report)

Oruka Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel peptide‐based therapies for oncology. The company's proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell‐permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company's lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.